Impax announced the launch of Oxymorphone HCl Extended-Release Tablets, the generic version of Endo‘s Opana ER. Opana ER is indicated for moderate to severe pain when the use of a continuous, around-the-clock opioid is required for an extended period of time; not for “as-needed” use.
Oxymorphone, an opioid agonist, is relatively selective for the mu receptor, although it can interact with other opioid receptors at higher doses. Specific central nervous system (CNS) opiate receptors and endogenous compounds with morphine-like activity have been identified throughout the brain and spinal cord and are likely to play a role in the expression and perception of analgesic effects.
Impax is commencing shipment of Oxymorphone HCl Extended-Release Tablets through Global Pharmaceuticals in 5mg, 7.5mg, 10mg, 15mg, 20mg, 30mg, and 40mg in 30-, 100-, and 1000-count bottles.
For more information call (510) 240-6000 or visit www.impaxlabs.com.